SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 1,294.26 |
Enterprise Value ($M) | 1,271.30 |
Book Value ($M) | 700.91 |
Book Value / Share | 39.59 |
Price / Book | 1.85 |
NCAV ($M) | 105.28 |
NCAV / Share | 5.95 |
Price / NCAV | 12.29 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.07 |
Return on Assets (ROA) | 0.07 |
Return on Equity (ROE) | 0.09 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 12.72 |
Current Ratio | 14.15 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 237.43 |
Assets | 833.06 |
Liabilities | 132.15 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 131.31 |
Operating Income | 9.82 |
Net Income | 52.15 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 49.58 |
Cash from Investing | -11.68 |
Cash from Financing | -59.95 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G | Macquarie Group Ltd | 5.66 | 57.97 | |
13G/A | Janus Henderson Group Plc | 7.70 | 7.00 | |
13G/A | Vanguard Group Inc | 10.76 | 1.81 | |
13G | Goldman Sachs Group Inc | 6.80 | ||
13G/A | BlackRock Inc. | 17.00 | 6.19 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
19,181 | 73,881 | 25.96 | |
49,203 | 191,807 | 25.65 | |
12,505 | 107,915 | 11.59 | |
15,674 | 107,055 | 14.64 | |
(click for more detail) |
Similar Companies | |
---|---|
KROS – Keros Therapeutics, Inc. | KYMR – Kymera Therapeutics, Inc. |
LBPH – Longboard Pharmaceuticals, Inc. | LNTH – Lantheus Holdings, Inc. |
LRMR – Larimar Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io